Introduction
Neutropenia after chemotherapy is one of several important risk factors for infection. Th e infection risk depends upon the duration of neutropenia and other patient-specifi c or therapy-specifi c factors. Th e most common symptom of infection is fever. Documented evidence of infection is present in only about 40% of patients [1, 2] . Physicians are often confronted with fever of unknown origin, and the therapeutic regimens are empiric or calculated on the basis of therapeutic trials. Because of the risk of rapid deterioration, empiric anti-infective therapy must be started immediately. Here we discuss recommendations for the diagnosis, therapy and prophylaxis of febrile neutropenia after chemotherapy, excluding the context after allogenic stem-cell transplantation.
Febrile neutropenia

Defi nitions -risk assessment
Neutropenia is classifi ed in intrinsic defects, like cyclic neutropenia, and acquired causes. In this article, we focus upon chemotherapy-induced neutropenia, the major cause of acquired neutropenia. Clinically signifi cant neutropenia, associated with an increased risk for infection, is defi ned as a neutrophil count below 500/μl, whereas a count below 100/μl is considered as severe neutropenia. Patients with an absolute neutrophil count predicted to drop to below 500/μl in the next two days are also considered as having signifi cant neutropenia. In terms of chemotherapy-induced neutropenia, the discrimination between a duration of less than or equal 7 days (referred to as a standard risk for infection) and a prolonged duration of over 7 days (referred to as a high risk for infection, i.e. after induction therapy for acute myelogenic leukaemia) [3] is relevant to the management of neutropenia. Patients after autologous stem cell transplantation cannot be explicitly assigned to either of these groups, because the duration of neutropenia is usually between 6 and 10 days. We shall not address the unique situation after allogenic transplantation in this report.
Inclusion of additional parameters predicting the outcome of febrile neutropenia led to a scoring system (Multinational Association for Supportive Care in Cancer = MASCC Score) that may defi ne a carefully selected patient group for outpatient antibiotic treatment (Table 1 ; a risk score of >2.1 identifi es low risk patients) [4, 5] .
Fever in neutropenia is defi ned as an oral temperature of 38.3°C once, or a temperature of 38.0°C twice within 12 h or lasting longer than 1 h. Even if there are other possible reasons for fever-like B-symptoms, reaction against medication or blood products, it must be assumed that the cause of fever in neutropenia is an infection. Fever occurs in 10 to 50% of patients after chemotherapy for solid tumours during neutropenia and in more than 80% after chemotherapy for haematological malignancies [6] . Some patients do not develop review 31 © Springer-Verlag fever (i.e. under treatment with steroids or pain medication like novaminsulfon), but show signs of infections. Th ese patients should be treated in the same way as with fever in neutropenia.
Diagnostic evaluation
In the presence of fever, in accordance with the aforementioned defi nition, immediate anti-infective treatment should be started and diagnostics be performed. Diagnostics should include clinical examination (mandatory every day or twice a day), assessing any changes in skin and mucosa, exit sites of central and peripheral venous access, upper and lower respiratory tracts, urogenital tract, abdomen and perianal region, and the monitoring of blood pressure, pulse rate and respiratory frequency.
-At least 2 pairs of blood cultures: two from each lumen of central venous access and at least two from a peripheral vein. -Complete blood cell count including neutrophil count and platelets -Serum levels of creatinine, electrolytes, ALAT, ASAT, alkaline phosphatase, gamma-GT, bilirubin, INR, PTT, CRP -Other cultures from sites of suspected infections -A chest CT scan (alternatively chest X-ray) in case of pulmonary symptoms
Anti-infective treatment of febrile neutropenia
Fever occurs in 10-50% of patients after chemotherapy for solid tumours during neutropenia and in more than 80% after chemotherapy for haematological malignancies. Despite diagnostic procedures, the source of infection can be identifi ed in only 40% of fever episodes [1, 2] and only 23% of episodes are associated with a positive blood culture [7] . Th erefore, the spectrum of empiric antimicrobial treatment must cover gram-negative aerobic bacteria (enterobacteriaceae and pseudomonas aeruginosa), gram-positive cocci (streptococci, staphylococcus aureus and enterococci), and it should be adapted to the local resistance profi le (i.e. MRSA, VRE and ESBL-producing bacteriae). Anaerobic pathogens or fungi do not have to be considered in the fi rst-line empiric anti-infective regimen. Th e most common pathogens are listed in Table 2 [8]. Without antibiotic prophylaxis, gram-negative cocci are the most often isolated pathogens. When using antibiotic prophylaxis, there is a trend toward gram-positive cocci [9] . Th e interpretation of microbiological results must consider that positive cultures for coagulase-negative staphylococci or corynebacteriae often resemble contamination. It is therefore recommended that only two positive cultures detecting these pathogens be considered as relevant. Furthermore, results from positive cultures should be used to include these pathogens in the anti-infective regimen, but not to narrow the treatment's spectrum. Anti-infective therapy must be initiated immediate, because any delay can worsen the prognosis of patients with infection in neutropenia [10] . It is important not to wait for diagnostic fi ndings before starting therapy.
Th e ideal choice of empiric antibiotics is a broad-spectrum regimen, covering the most common pathogens. Single agent regimens have been proven to be equivalent to combination treatment [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] . Th us a fi rst-line treatment with a pseudomonas aeroginosa-covering β-lactam antibiotic is recommended. Specifi cally, piperacillin/tacobactam, ceftazidime, cefepime, imipenem or meropenem are recommended. Because of the increase in ESBL-producing organisms, the use of cephalosporins is questionable [21] , and there is reluctance to use cefepime, because that agent might be associated with an increase in mortality compared to alternative antibiotic regimens [22] . A combination with aminoglycosides is discouraged [23] . Th e addition of glycopeptides should be restricted to patients with suspected se- vere mucositis, skin or soft-tissue infection, or a suspected foreign body (e.g. central venous access)-related infection. Included in empirical fi rst-line treatment, it does not improve outcome [24] . Th e median time to defervescence in patients with haematological malignancies is about 5 days [25] , and in patients with solid tumours and low risk about 2 days [26] .
For patients with persistent fever and no clinical improvement after 72 to 96 hours, it is recommended to repeat the aforementioned diagnostic procedures and to switch an empirical anti-infective regimen if there is no detectable infection source. Th e gaps in the gram-negative spectrum should be closed. Th us after piperacillin/tacobactam or cephalosporine as fi rst-line, imipenem or meropenem is a reasonable choice. After fi rst-line carbapenem, the addition of an aminoglycoside or glycopeptide should be considered. In the high-risk group (expected duration of neutropenia >7 days) the addition of empiric antimycotic treatment should be considered if the infection is not under control after 4 to 7 days of antibiotic treatment. A pre-emptive approach for high-risk patients using information from CT scans and blood tests (such as the serum galactomannan test in combination with clinical evidence) have resulted in reduced antifungal treatment (7.7% of patients) compared to an empirical strategy (35% qualifi ed for empirical antifungal treatment) without compromising patient outcomes [27] . Liposomal amphotericin-B, caspofungin or voriconazol are reasonable choices for empirical antifungal treatment in high-risk patients showing a risk for aspergillus infection. Clinically unstable patients on antimycotic prophylaxis active against aspergillus should switch to empirical treatment with an antifungal agent of another class. Unless there is a documented or suspected viral infection, no antiviral therapy is indicated.
Only those patients with an expected duration of neutropenia of under 7 days and assignment to the low-risk category according to the MASCC score should be managed in an outpatient setting with oral antibiotics (amoxicillin/clavulanate in combination with ciprofl oxacin or levofl oxacin) [4, 28] . Fluorochinolones have gaps in the gram-positive spectrum and should not be used as single therapy. Also, there is no indication for fl uorochinolones after fl uorochinolone prophylaxis. If there is no defervescence and the patients are not clinically stable, they should be hospitalised and intravenous antibiotic treatment must be started empirically, e.g. with piperacillin/tazobactam. Anti-infective treatment must be continued for two days after defervescence and a neutrophil count >500/μl. Documented infections may be handled diff erently, as pneumonias or soft-tissue infections must be treated for 10 to 14 days, independently from neutrophil recovery.
We do not specifi cally address herein all situations involving documented infection, but the anti-infective regimen should cover the documented infection and still cover the broad spectrum of empiric treatment.
Role of haematopoietic growth factors
Concerning neutropenic fever, G-CSF (granulocyte-colonystimulating factor) is the most important haematopoietic growth factor worthy of discussion.
In several studies, the use of G-CSF has been shown to reduce the incidence of neutropenic fever and infection-related mortality. According to a meta-analysis of 17 randomised trials, most demonstrated a benefi t of G-CSF independent of the basic risk of febrile neutropenia in the specifi c trial [29] . Th us it is recommended that G-CSF be used as primary prophylaxis in patients undergoing chemotherapy with a risk of ≥20% febrile neutropenia [3] , particularly in those with additional risk factors like older age, comorbidities such as liver, kidney, lung or cardiac disease, poor Karnofsky performance status, or an impaired immune system. After an episode of febrile neutropenia, patients should receive G-CSF after the next course of chemotherapy as secondary prophylaxis. Th ere is no indication for prophylactic G-CSF with a risk of febrile neutropenia of ≤10%. Patients in the risk group between 10 and 20% should be evaluated individually regarding the other risk factors.
In the specifi c situation after autologous stem cell transplantation, where patients have a risk of neutropenic fever of approximately 60%, G-CSF reduces the risk of fever, infection, reduces the number of days on antibiotic treatment, but has no signifi cant infl uence on outcome and mortality. Its use is therefore optional.
Th e interventional approach starting G-CSF in the context of neutropenic fever has not been shown to improve outcome. Th e results for reducing the days on antibiotics and duration of hospitalisation are inconsistent [30, 31] . None of the guidelines (2010 update of the Guideline by the "Infectious Diseases Society of America" (IDSA) and Guideline of the "Deutsche Gesellschaft fuer Haematologie und Onkologie" (DGHO)) advocate using G-CSF in this situation.
Th e diff erent active substances (lenograstim, fi lgrastim, PEG-fi lgrastim) display equivalent eff ects [29] and can be used in the situations described above. GM-CSF (granulocyte-macrophage-colony stimulating factor) plays no role in febrile neutropenia.
Prophylaxis with anti-infective agents
Th ere is good evidence of the effi cacy of antibiotic anti-infective prophylaxis during neutropenia. We have been aware for many years that febrile episodes and documented infections can be reduced [32] . Fluorochinolones have been well studied. In a randomised trial, prophylaxis with levofl oxacin was very eff ective in reducing episodes of fever, documented infections, especially gram-negative bacterial infections [33] .
High-risk patients with profound neutropenia for more than 7 days also show a survival benefi t. Despite the potential risk of inducing resistant pathogens [34, 35] , antibiotic prophylaxis is recommended in this particular patient group. Patients after autologous stem-cell transplantation also benefi t, but a survival advantage has not been observed. Th erefore most guidelines do not recommend antibiotic prophylaxis in these patients.
Nor do low-risk patients with solid tumours or lymphoma benefi t routinely from a prophylactic approach. Even if there is a reduction in febrile episodes, there is no diff erence in documented infections compared to the placebo group [36] in that patient population.
Th e duration of prophylaxis should start before neutropenia, that is after fi nishing chemotherapy and continued until the neutrophils rise above 500/μl or empirical antibiotic therapy is started.
Although the risk for fungal infection is relatively high after allogenic transplantation, we do not address this situation discussed in this paper.
Risk for candida infection is higher when the mucosal barrier has been damaged [37] e.g. induced by intensive chemotherapy. Th e risk for fungal infections is highest in patients with persistent, [38, 39] profound neutropenia. Patients undergoing intensive induction chemotherapy for acute leukaemia are at risk for candida and aspergillus infections [40] . Prophylactic approaches should cover both groups of fungal pathogens. A randomised study showed posaconazole to be superior to fl uconazole or itraconazole [41] . Even if there are problems with absorption and drug interaction (coadministration with chemotherapy should be avoided), in the posaconazole group, the rate of aspergillus infections was reduced to 1%, compared to 7% with the other antifungal agents. Posaconazole prophylaxis is therefore indicated in these patients.
In patients with prior invasive aspergillus infection who are expected to experience a chemotherapy-induced period of neutropenia especially of more than 7 days, a secondary prophylaxis with a mold-active antifungal agent is recommended.
Conclusion
Febrile neutropenia is one of the complications after chemotherapy carrying a relevant risk for death. It is now considered standard therapy in several high-risk patient groups to use anti-infective prophylaxis to prevent infection, and in patients with a risk for febrile neutropenia of ≥20%, to use G-CSF. Besides the prophylactic approach, it is important to deal with febrile neutropenia by employing adequate diagnostic procedures, but not to delay the appropriate therapy. Empiric antibiotic treatment should start immediately. A change of antimicrobial therapy is mandatory after a suffi cient duration of therapy and clinical deterioration or an unstable situation and might be considered in case of persisting fever. Here the coverage of the spectrum of pathogens by the anti-infective treatment has to be adapted to the risk profi le of the patient. Knowledge of the local epidemic situation, especially for resistant pathogens is essential for an appropriate choice of calculated or empiric antibiotic therapy. Documented infections must be incorporated in the strategy, but the spectrum of anti-infective treatment should not be narrowed.
